ATE331510T1 - Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen - Google Patents

Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen

Info

Publication number
ATE331510T1
ATE331510T1 AT02023126T AT02023126T ATE331510T1 AT E331510 T1 ATE331510 T1 AT E331510T1 AT 02023126 T AT02023126 T AT 02023126T AT 02023126 T AT02023126 T AT 02023126T AT E331510 T1 ATE331510 T1 AT E331510T1
Authority
AT
Austria
Prior art keywords
fatty acids
polyunsaturated fatty
seizures
cardiovascular
primary prevention
Prior art date
Application number
AT02023126T
Other languages
English (en)
Inventor
Hajime Shibuya
Original Assignee
Pro Aparts Investimentos E Con
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448595&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE331510(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pro Aparts Investimentos E Con filed Critical Pro Aparts Investimentos E Con
Application granted granted Critical
Publication of ATE331510T1 publication Critical patent/ATE331510T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02023126T 2001-11-12 2002-10-15 Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen ATE331510T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI002384A ITMI20012384A1 (it) 2001-11-12 2001-11-12 Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori

Publications (1)

Publication Number Publication Date
ATE331510T1 true ATE331510T1 (de) 2006-07-15

Family

ID=11448595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02023126T ATE331510T1 (de) 2001-11-12 2002-10-15 Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen

Country Status (10)

Country Link
US (4) US20030100610A1 (de)
EP (1) EP1310249B1 (de)
JP (1) JP4731789B2 (de)
AT (1) ATE331510T1 (de)
CY (1) CY1105119T1 (de)
DE (1) DE60212786T2 (de)
DK (1) DK1310249T3 (de)
ES (1) ES2262741T3 (de)
IT (1) ITMI20012384A1 (de)
PT (1) PT1310249E (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
KR101255650B1 (ko) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 새로운 ｄｈａ 유도체 및 약제로서의 용도
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
AU2006242914B2 (en) 2005-05-04 2012-02-02 Pronova Biopharma Norge As New DHA derivatives and their use as medicaments
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
CA2570763C (en) * 2005-07-08 2011-08-23 Mochida Pharmaceutical Co., Ltd. Composition for preventing onset of cardiovascular events
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
CA2634139C (en) * 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
JP2010508262A (ja) 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
CN101535238A (zh) 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20100266681A1 (en) * 2006-11-03 2010-10-21 Anne Kristin Holmeide Fatty acid alcohols
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
MX2011001419A (es) 2008-08-07 2011-05-25 Prodotti Antibiotici Spa Tratamiento a largo plazo de deficiencia cardiaca sintomatica.
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
AU2014203034B2 (en) * 2009-04-29 2016-09-15 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
WO2010127103A1 (en) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
NZ600167A (en) * 2009-10-29 2014-06-27 Acasti Pharma Inc Concentrated therapeutic phospholipid compositions
RU2728825C2 (ru) * 2010-03-04 2020-07-31 Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012108379A1 (ja) * 2011-02-07 2012-08-16 持田製薬株式会社 拡張性うっ血性心不全治療剤
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US20120302639A1 (en) 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
JP2014506891A (ja) 2011-02-16 2014-03-20 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
EP2675446A1 (de) 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Omega-3-formulierungen mit epa, dha und dpa zur behandlung von risikofaktoren für kardiovaskuläre erkrankungen
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US20140191573A1 (en) * 2011-09-24 2014-07-10 Kool Koncepts Limited Energy management system
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP3348262A1 (de) 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Verfahren zur herstellung von dpa-angereicherten zusammensetzungen von mehrfach ungesättigten omega-3-fettsäuren in freier säureform
EP2800469B1 (de) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014011895A2 (en) * 2012-07-11 2014-01-16 Thetis Pharmaceuticals Llc High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
US11622952B2 (en) 2017-08-15 2023-04-11 Evonik Operations Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
JP2022543283A (ja) 2019-08-08 2022-10-11 エボニック オペレーションズ ゲーエムベーハー 多価不飽和脂肪酸塩を製造するための下流処理
WO2021023857A1 (en) 2019-08-08 2021-02-11 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
WO2021197969A1 (en) * 2020-04-01 2021-10-07 Evonik Operations Gmbh Preparation for use as vasorelaxant
WO2021197971A1 (en) * 2020-04-01 2021-10-07 Evonik Operations Gmbh Preparation for use as antioxidant
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4805062A (en) 1986-10-15 1989-02-14 Hitachi, Ltd. DC circuit breaker and method of commutation thereof
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4918104A (en) * 1987-06-16 1990-04-17 Weiss Howard S Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH0225447A (ja) 1988-07-13 1990-01-26 Nippon Oil & Fats Co Ltd 高度不飽和脂肪酸類の製造方法
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
GB9125602D0 (en) 1991-12-02 1992-01-29 Efamol Holdings Method of preventing reocclusion of arteries
CN1082909A (zh) 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH06263634A (ja) * 1993-03-10 1994-09-20 Sagami Chem Res Center カルシウム拮抗薬
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5541225A (en) 1994-10-11 1996-07-30 The General Hospital Corporation α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia
NL9401743A (nl) 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
PL186618B1 (pl) 1995-11-28 2004-02-27 Braun Melsungen Ag Izotoniczna emulsja lipidowa do podawania pozajelitowego i jej zastosowanie
IT1277953B1 (it) 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JPH10139664A (ja) * 1996-11-12 1998-05-26 Sagami Chem Res Center 抗不整脈薬
JPH11239464A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 運動時の危険因子除去能を有する組成物
DE69842121D1 (de) 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
AU3846801A (en) * 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
DK1157692T3 (da) * 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP4337273B2 (ja) * 2001-04-20 2009-09-30 日本水産株式会社 基礎代謝増進剤
EP1279400A1 (de) * 2001-07-25 2003-01-29 Target Hit sa Änderung der Fettsäurezusammensetzung Organ- und Gewebe-Zellmembranen
AU784852B2 (en) * 2001-08-10 2006-07-06 Mars, Incorporated Canine support diet
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030144219A1 (en) 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
WO2008066745A1 (en) 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Also Published As

Publication number Publication date
CY1105119T1 (el) 2009-11-04
EP1310249A1 (de) 2003-05-14
US20100016428A1 (en) 2010-01-21
ES2262741T3 (es) 2006-12-01
PT1310249E (pt) 2006-09-29
US20030100610A1 (en) 2003-05-29
JP2003146874A (ja) 2003-05-21
US20040162349A1 (en) 2004-08-19
US20080269331A1 (en) 2008-10-30
ITMI20012384A1 (it) 2003-05-12
DE60212786T2 (de) 2007-06-28
DE60212786D1 (de) 2006-08-10
DK1310249T3 (da) 2006-09-25
EP1310249B1 (de) 2006-06-28
US7553870B2 (en) 2009-06-30
US7619002B2 (en) 2009-11-17
JP4731789B2 (ja) 2011-07-27
US8648061B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
ATE331510T1 (de) Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen
DE69622722D1 (de) Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
DK1157692T3 (da) Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
HK1058883A1 (en) Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders.
TR199900786T2 (xx) Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler.
DK1152755T3 (da) Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde
EP0292846A3 (en) A process for the extraction of polyunsaturated fatty acid esters from fish oils and pharmaceutical and/or dietetic compositions containing said esters
EP0302482A3 (de) Freie Fettsäuren zur Behandlung oder Prophylaxe von rheumatoider Arthritis
DK1121115T4 (da) PUFA-tilskud
ATE75502T1 (de) Verfahren zur herstellung von polyungesaettigten fettsaeuren.
UA89207C2 (ru) Применение длинноцепочечных полиненасыщенных жирных кислот для получения жидкой питательной смеси для кормления детей
WO2004078166A3 (en) Use of omega-3-fatty acids in the treatment of diabetic patients
KR940018091A (ko) 불포화 지방산을 포함하는 처방
DK0623019T3 (da) Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
PT804411E (pt) Analogos sinteticos de acidos gordos poli-insaturados
AU2441400A (en) Stabilized lipidic composition, method for the preparation thereof and nutritional product containing the same
FR2843124B1 (fr) Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
RU93049092A (ru) Лечение жирными кислотами
DE60329588D1 (de) Verwendung von epa and dha zur sekundären prevention von schlaganfällen
NO932984L (no) Fettsyrebehandling
NZ304924A (en) hybridised triglycerides
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1310249

Country of ref document: EP